Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.
A Double-blind Study Evaluating the Efficacy and Safety of the Combination of Etanercept and Methotrexate in Comparison to Etanercept Alone or Methotrexate Alone in Rheumatoid Arthritis Patients.
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
This PHASE3 trial investigates Active Rheumatoid Arthritis and is currently completed. Wyeth is now a wholly owned subsidiary of Pfizer leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jan 2024 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE3
First recorded
Oct 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wyeth is now a wholly owned subsidiary of Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia, Alkmaar, Netherlands, Arnhem, Netherlands, Athens, Greece, Barcelona, Spain, Berlin, Germany, Bordeaux, France, Brest, France, Brussels, Belgium, Bucharest, Romania and 72 more location s